Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencySat, 08 Jun 2024 14:23:14 +0200Fri, 05 Apr 2024 16:04:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Recarbrio, relebactam (MK-7655A),cilastatin sodium,imipenem monohydrate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0090/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001809-pip01-15-m03Opinion/decision on a Paediatric investigation plan (PIP): Recarbrio, relebactam (MK-7655A),cilastatin sodium,imipenem monohydrate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0090/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001809-pip01-15-m03Fri, 05 Apr 2024 16:04:00 +0200Human medicine